Hormone Therapy Usage Is Associated With Adverse Cardiovascular Events in Prostate Cancer Patients of the All of Us Research Program Cohort
The Prostate · 2025
DOI: 10.1002/pros.24913 ↗At a glance
Journal article in The Prostate, 2025. Written by Yuanchu J Yang and 7 co-authors. Institution: Vanderbilt University School of Medicine, Nashville, Tennessee, USA. Major MEDLINE topics: Prostatic Neoplasms, Cardiovascular Diseases, Antineoplastic Agents, Hormonal. Cited 1 times so far (Crossref); 44 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: This research was supported by the National Human Genome Research Institute., Intramural NIH HHS, National Human Genome Research Institute.
Topics: Onkologische Pflege
Abstract (original language)
Background
Hormone therapy (HT) has greatly improved overall survival for prostate cancer patients, but may also influence cardiovascular health in an already high‐risk population.
Methods
This retrospective cohort study examined participants in the All of Us Research Program with prostate cancer, had no prior history of adverse cardiovascular events, and were either treated or not treated with HT. HT was defined as GnRH agonists, GnRH antagonists, abiraterone, androgen antagonists, or androgen receptor pathway inhibitors. We defined adverse cardiovascular event as myocardial infarctions, heart failure, or strokes. Time to adverse cardiovascular event was defined using longitudinal electronic health record data. We evaluated whether HT use affected the risk of adverse cardiovascular events using a Cox regression model adjusted for established cardiovascular risk factors.
Results
The final cohort included 5156 participants. After adjustment for cardiovascular risk covariates, HT treatment was associated with increased risk of adverse cardiovascular event (HR: 1.22; 95% CI: 1.01–1.48; p = 0.03). In participants with pre‐treatment dyslipidemia, HT usage was associated with increased risk of adverse cardiovascular events (HR: 1.52; 95% CI: 1.19–1.95; p < 0.001). In participants without pre‐treatment dyslipidemia, no association was found (HR: 0.96; 95% CI: 0.71–1.30; p = 0.81).
Conclusions
Our results show that HT‐associated cardiovascular risk may be synergistically amplified by dyslipidemia. These results suggest that risk stratification by dyslipidemia status may improve cardiovascular outcomes for prostate cancer survivors.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
- Precision Health Informatics Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA.
- Academic Internship Program, National Institutes of Health, Bethesda, Maryland, USA.
- Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA.
- All of Us Research Program, Office of the Director, National Institutes of Health, Bethesda, Maryland, USA.
ORCID profiles: Yuanchu J Yang, Chenjie Zeng
Funding
- This research was supported by the National Human Genome Research Institute.
- Intramural NIH HHS
- National Human Genome Research Institute
Cite
APA
Yang, Y. J., Zeng, C., Schaffer, K. R., Tran, T. C., Sauer, P. J., Brown, L. A., Park, B. H., & Denny, J. C. (2025). Hormone Therapy Usage Is Associated With Adverse Cardiovascular Events in Prostate Cancer Patients of the All of Us Research Program Cohort. The Prostate. https://doi.org/10.1002/pros.24913
Vancouver
Yang YJ, Zeng C, Schaffer KR, Tran TC, Sauer PJ, Brown LA, et al. Hormone Therapy Usage Is Associated With Adverse Cardiovascular Events in Prostate Cancer Patients of the All of Us Research Program Cohort. The Prostate. 2025. doi:10.1002/pros.24913
BibTeX
@article{Yang2025,
author = {Yang, Yuanchu J and Zeng, Chenjie and Schaffer, Kerry R and Tran, Tam C and Sauer, Peter J and Brown, Lincoln A and Park, Ben H and Denny, Joshua C},
title = {Hormone Therapy Usage Is Associated With Adverse Cardiovascular Events in Prostate Cancer Patients of the All of Us Research Program Cohort},
journal = {The Prostate},
year = {2025},
doi = {10.1002/pros.24913}
}
EUVIMED